ArticleEClinicalMedicine2023

Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.

Stefania Oliva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.